血管前置研究核心结局集与报告清单
血管前置发生率0.46/1000妊娠,胎儿及新生儿死亡和并发症发生率高。该调查于2021年3月14日至2022年10月4日开展两轮国际跨学科Delphi调查及线上共识会议,邀请医疗专业人员与健康服务使用者参与。204名参与者(115名健康服务使用者、89名医疗专业人员,来自27个国家)对系统评价和定性访谈识别的67项结局进行评分,最终确定13项核心结局,并同步制定22项报告清单。作者希望该核心结局集与报告清单能促进未来研究纳入患者重要结局,实现数据统一、改善证据合成并推动临床实践指南制定。
要点
- 血管前置为罕见病,发生率为0.46/1000妊娠,胎儿及新生儿死亡和并发症发生率高。
- 204名参与者(115名健康服务使用者与89名医疗专业人员,来自27个国家)参与两轮线上Delphi调查,对67项结局进行评分。
- 最终确定13项核心结局,包括活产、胎儿丢失(流产或死胎)或新生儿死亡、严重新生儿并发症、胎儿/新生儿失血、新生儿重症监护病房入住>24小时、出生胎龄等。
- 同步制定22项报告清单,纳入血管前置研究中尽可能重要和/或相关的条目。
- 作者希望核心结局集与报告清单能推动未来研究纳入患者重要结局,促进数据统一、证据合成及临床实践指南制定。
适用人群与场景
- 血管前置孕妇的围产期筛查、诊断与管理研究。
- 参与制定核心结局集的人群为医疗专业人员与健康服务使用者。
研究设计与关键结果
- 研究类型为调查性研究,采用两轮国际跨学科Delphi调查及线上共识会议,于2021年3月14日至2022年10月4日进行。
- 204名参与者(115名健康服务使用者与89名医疗专业人员,来自27个国家)参与,对系统评价和定性访谈识别的67项结局进行两轮线上Delphi评分。
- 最终确定13项核心结局:妊娠结局(活产、胎儿丢失[流产或死胎]或新生儿死亡)、严重新生儿并发症、胎儿/新生儿失血、新生儿重症监护病房入住>24小时、出生胎龄、妊娠晚期确认血管前置诊断、神经认知与发育结局、分娩方式、孕产妇死亡或严重并发症、孕产妇生活质量、产前住院时长、产前或围产期出血。
- 同步制定22项报告清单,纳入血管前置研究中尽可能重要和/或相关的条目。
证据类型、等级与局限
- 证据类型:国际跨学科Delphi调查及共识会议(调查性研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者希望核心结局集与报告清单能鼓励研究者在未来研究中纳入患者重要结局,以实现数据统一、改善证据合成,并促进针对这一罕见且高致死疾病的临床实践指南制定;及时诊断和管理可能预防胎儿及孕产妇并发症和死亡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Vasa previa, although a rare condition affecting 0.46 per 1000 pregnancies, results in high rates of fetal and neonatal mortality and morbidity. Widespread use of a core outcome set and reporting checklist may enable data harmonization, enhance evidence synthesis, and ensure prioritization of patient-important outcomes in clinical practice, future research, and clinical practice guidelines.
OBJECTIVE: To develop a core outcome set for studies on vasa previa that includes perinatal screening, diagnosis, and management of vasa previa.
DESIGN, SETTING, AND PARTICIPANTS: This survey study involved a 2-round international and cross-disciplinary Delphi survey and virtual consensus meetings conducted between March 14, 2021, and October 4, 2022. Health care professionals (HCPs) and health service users (HSUs) were invited to participate in the development of the core outcome set.
EXPOSURE: Perinatal screening, diagnosis, and management of vasa previa.
MAIN OUTCOME AND MEASURES: Core outcomes and reporting checklist items for future studies on vasa previa were developed using Delphi surveys, small group discussions, and a consensus meeting.
RESULTS: An international group of 204 participants, comprising 115 HSUs and 89 HCPs representing 27 countries, rated 67 outcomes identified through a systematic review and qualitative interviews in a 2-round online Delphi survey. Through virtual small group discussions and a consensus meeting, 13 core outcomes were identified: pregnancy outcome (live birth, fetal loss [miscarriage or stillbirth], or neonatal death), severe neonatal morbidity, fetal/neonatal blood loss, neonatal intensive care unit admission for >24 hours, gestational age at birth, third trimester confirmation of vasa previa diagnosis, neurocognitive and developmental outcomes, mode of birth, maternal death or severe morbidity, maternal quality of life, duration of antepartum admission, and antepartum or peripartum hemorrhage. A 22-item reporting checklist was simultaneously developed to include important items in studies on vasa previa when possible and/or relevant.
CONCLUSIONS AND RELEVANCE: The core outcome set and reporting checklist for vasa previa are hoped to encourage researchers to incorporate patient-important outcomes in future studies to enable data harmonization, improve evidence synthesis, and facilitate the development of clinical practice guidelines for this rare and highly lethal condition for which timely diagnosis and management may prevent fetal and maternal morbidity and mortality.
参考来源
- Yeretsian T, Javid N, Hirschhorn-Edwards N, et al. Core Outcome Set and Reporting Checklist for Studies on Vasa Previa. JAMA Netw Open. 2025. PMID: 40100217. doi:10.1001/jamanetworkopen.2025.1000
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。